Works matching IS 08876924 AND DT 2008 AND VI 22 AND IP 7

Results: 29

Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1428, doi. 10.1038/sj.leu.2405060

By:

Hasle, H;
Abrahamsson, J;
Arola, M;
Karow, A;
O'Marcaigh, A;
Reinhardt, D;
Webb, D K H;
van Wering, E;
Zeller, B;
Zwaan, C M;
Vyas, P

Publication type:

Article

Sirolimus enhances the effect of apoptotic cell infusion on hematopoietic engraftment and tolerance induction.

Published in:

2008

By:

Bonnefoy, F;
Masson, E;
Perruche, S;
Marandin, A;
Borg, C;
Radlovic, A;
Shipman, B;
Tiberghien, P;
Saas, P;
Kleinclauss, F

Publication type:

Letter

Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1434, doi. 10.1038/sj.leu.2405063

By:

Van Vlierberghe, P;
Beverloo, H B;
Buijs-Gladdines, J;
van Wering, E R;
Horstmann, M;
Pieters, R;
Meijerink, J P P

Publication type:

Article

Induction of Toll-like receptor 2 and 4 expression on CD4+ and CD8+ T cells in G-CSF-mobilized unrelated peripheral blood stem cell grafts during leukapheresis: impact on patient outcome.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1438, doi. 10.1038/sj.leu.2405075

By:

Platzbecker, U;
Stoehlmacher, J;
Pabst, C;
Goekkurt, E;
Oelschlägel, U;
Schirutschke, H;
Hölig, K;
Theuser, C;
Mogck, U;
Ehninger, G;
Bornhäuser, M

Publication type:

Article

Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1446, doi. 10.1038/sj.leu.2405077

By:

Stamatopoulos, K;
Papadaki, T;
Pontikoglou, C;
Athanasiadou, I;
Stavroyianni, N;
Bux, J;
Batsis, I;
Pyrovolaki, K;
Paterakis, G;
Anagnostou, D;
Anagnostopoulos, A;
Papadaki, H A

Publication type:

Article

Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1449, doi. 10.1038/sj.leu.2405079

By:

Nishioka, C;
Ikezoe, T;
Yang, J;
Koeffler, H P;
Yokoyama, A

Publication type:

Article

MicroRNA expression in lymphocyte development and malignancy.

Published in:

2008

By:

Lawrie, C H;
Saunders, N J;
Soneji, S;
Palazzo, S;
Dunlop, H M;
Cooper, C D O;
Brown, P J;
Troussard, X;
Mossafa, H;
Enver, T;
Pezzella, F;
Boultwood, J;
Wainscoat, J S;
Hatton, C S R

Publication type:

Letter

Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1452, doi. 10.1038/sj.leu.2405085

By:

Brownlow, N;
Vaid, M;
Dibb, N J

Publication type:

Article

JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1454, doi. 10.1038/sj.leu.2405088

By:

Cambier, N;
Renneville, A;
Cazaentre, T;
Soenen, V;
Cossement, C;
Giraudier, S;
Grardel, N;
Laï, J-L;
Rose, C;
Preudhomme, C

Publication type:

Article

NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?

Published in:

2008

By:

Pasqualucci, L;
Li, S;
Meloni, G;
Schnittger, S;
Gattenlohner, S;
Liso, A;
Di Ianni, M;
Martelli, M P;
Pescarmona, E;
Foa, R;
Haferlach, T;
Skoda, R C;
Falini, B

Publication type:

Case Study

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

Published in:

2008

By:

Best, O G;
Gardiner, A C;
Majid, A;
Walewska, R;
Austen, B;
Skowronska, A;
Ibbotson, R;
Stankovic, T;
Dyer, M J S;
Oscier, D G

Publication type:

Letter

Two cases of hypereosinophilia and high-risk acute lymphoblastic leukemia.

Published in:

2008

By:

Sutton, R;
Lonergan, M;
Tapp, H;
Venn, N C;
Haber, M;
Norris, M D;
O'Brien, T A;
Alvaro, F;
Revesz, T

Publication type:

Case Study

Preclinical targeting of NF-κB and FLT3 pathways in AML cells.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1466, doi. 10.1038/sj.leu.2405102

By:

Griessinger, E;
Frelin, C;
Cuburu, N;
Imbert, V;
Dageville, C;
Hummelsberger, M;
Sirvent, N;
Dreano, M;
Peyron, J-F

Publication type:

Article

Genomic and molecular switching in relapsed acute promyelocytic leukemia.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1469, doi. 10.1038/sj.leu.2405103

By:

Albano, F;
Pannunzio, A;
Anelli, L;
Zagaria, A;
Liso, V;
Rocchi, M;
Specchia, G

Publication type:

Article

Is BAL useful in patients with acute myeloid leukemia admitted in ICU for severe respiratory complications?

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1361, doi. 10.1038/leu.2008.100

By:

Rabbat, A;
Chaoui, D;
Lefebvre, A;
Roche, N;
Legrand, O;
Lorut, C;
Rio, B;
Marie, J-P;
Huchon, G

Publication type:

Article

Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1368, doi. 10.1038/leu.2008.112

By:

Puigdecanet, E;
Espinet, B;
Lozano, J J;
Sumoy, L;
Bellosillo, B;
Arenillas, L;
Álvarez-Larrán, A;
Solé, F;
Serrano, S;
Besses, C;
Florensa, L

Publication type:

Article

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1299, doi. 10.1038/leu.2008.113

By:

Vannucchi, A M;
Antonioli, E;
Guglielmelli, P;
Pardanani, A;
Tefferi, A

Publication type:

Article

The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1308, doi. 10.1038/leu.2008.119

By:

Orazi, A;
Germing, U

Publication type:

Article

Treatment of plasma cell dyscrasias with lenalidomide.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1343, doi. 10.1038/leu.2008.123

By:

Dimopoulos, M A;
Kastritis, E;
Rajkumar, S V

Publication type:

Article

Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1395, doi. 10.1038/leu.2008.125

By:

Mony, U;
Jawad, M;
Seedhouse, C;
Russell, N;
Pallis, M

Publication type:

Article

Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1354, doi. 10.1038/leu.2008.126

By:

MacPartlin, M;
Smith, A M;
Druker, B J;
Honigberg, L A;
Deininger, M W

Publication type:

Article

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Published in:

2008

By:

Walz, C;
Cross, N C P;
Van Etten, R A;
Reiter, A

Publication type:

journal article

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

Published in:

2008

By:

Pineda-Roman, M;
Zangari, M;
van Rhee, F;
Anaissie, E;
Szymonifka, J;
Hoering, A;
Petty, N;
Crowley, J;
Shaughnessy, J;
Epstein, J;
Barlogie, B

Publication type:

journal article

Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1335, doi. 10.1038/leu.2008.162

By:

Emanuel, P D

Publication type:

Article

Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.

Published in:

2008

By:

Shammas, M A;
Koley, H;
Bertheau, R C;
Neri, P;
Fulciniti, M;
Tassone, P;
Blotta, S;
Protopopov, A;
Mitsiades, C;
Batchu, R B;
Anderson, K C;
Chin, A;
Gryaznov, S;
Munshi, N C

Publication type:

journal article

Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.

Published in:

2008

By:

Wu, L X;
Xu, J H;
Zhang, K Z;
Lin, Q;
Huang, X W;
Wen, C X;
Chen, Y Z

Publication type:

journal article

HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1387, doi. 10.1038/leu.2008.90

By:

Rutten, C E;
van Luxemburg-Heijs, S A P;
Griffioen, M;
Marijt, E W A;
Jedema, I;
Heemskerk, M H M;
Posthuma, E F M;
Willemze, R;
Falkenburg, J H F

Publication type:

Article

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial.

Published in:

Leukemia (08876924), 2008, v. 22, n. 7, p. 1377, doi. 10.1038/leu.2008.96

By:

Ritgen, M;
Böttcher, S;
Stilgenbauer, S;
Bunjes, D;
Schubert, J;
Cohen, S;
Humpe, A;
Hallek, M;
Kneba, M;
Schmitz, N;
Döhner, H;
Dreger, P

Publication type:

Article

Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation.

Published in:

2008

By:

Jamal, R;
Bélisle, C;
Lessard, M-C;
Hébert, J;
Roy, D-C;
Levine, R;
Busque, L;
Bélisle, C;
Hébert, J

Publication type:

Case Study

Works matching IS 08876924 AND DT 2008 AND VI 22 AND IP 7

Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML.

Sirolimus enhances the effect of apoptotic cell infusion on hematopoietic engraftment and tolerance induction.

Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia.

Induction of Toll-like receptor 2 and 4 expression on CD4<sup>+</sup> and CD8<sup>+</sup> T cells in G-CSF-mobilized unrelated peripheral blood stem cell grafts during leukapheresis: impact on patient outcome.

Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia.

Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21<sup>waf1</sup> promoter in acute myelogenous leukemia cell.

MicroRNA expression in lymphocyte development and malignancy.

Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro.

JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.

NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

Two cases of hypereosinophilia and high-risk acute lymphoblastic leukemia.

Preclinical targeting of NF-κB and FLT3 pathways in AML cells.

Genomic and molecular switching in relapsed acute promyelocytic leukemia.

Is BAL useful in patients with acute myeloid leukemia admitted in ICU for severe respiratory complications?

Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia.

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.

Treatment of plasma cell dyscrasias with lenalidomide.

Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.

Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.

Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.

Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.

HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia.

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial.

Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation.